under the guidance of the Global HIV Vaccine Enterprise, an alliance of
independent global organizations dedicated to accelerating preventative
AIDS vaccine development. The conference reported the AIDS epidemic
continuing as a global threat with the disease increasing in every
region of the world, especially East and Central Asia and Eastern
Europe where AIDS incidence was 21% higher in 2006 than in 2004.
Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the
AIDS Vaccine 2007 Conference included:
* GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate
anti-HIV/AIDS immune responses) at both low (1/10th) dose and full
* GeoVax vaccines were well tolerated with no or mild local and
systemic reactions in the majority of trial participants.
* 80% of both the low and full dose trial participants responded to
the vaccine which stimulated highly desirable anti-HIV T-cell
(white blood cell) and antibody responses.
* More volunteers had antibody responses to the full dose than to the
1/10th dose vaccine, whereas response rates for T cells were
similar for the 1/10th and full dose.
* 2nd MVA vaccination positively increased the number of CD8 T cell
responders and antibody responders.
* Excellent results led to authorization to start two new trials with
GeoVax HIV/AIDS vaccines which began in June 2007.
-- On September 21, 2007, Merck & Co., Inc. announced their candidate AIDS
vaccine failed to provide protection in a human study designed to test
for efficacy. In this Merck trial involving high risk volunteers, an
equal number of people received either placebo or AIDS vaccine. The
independent Data Safety Monitori
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved